Improving Patient Access to Care and Treatment Act

Bill: 117-hr-5950
Sponsor: full_name: Rep. Dean, Madeleine [D-PA-4]
Introduced: 2021-11-12
Policy area: Crime and Law Enforcement
Latest action: action_date: 2022-11-01
text: Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.

Summaries:
action_date: 2021-11-12
action_desc: Introduced in House
text: <p><strong>Improving Patient Access to Care and Treatment Act</strong></p> <p>This bill increases the number of days&#8212;from 14 to 60&#8212;within which a practitioner must administer certain narcotic drugs (e.g., buprenorphine) to a patient for maintenance or detoxification treatment (i.e., substance use disorder treatment) after receiving the drugs from a pharmacy.</p>

tv_txt: I 117th CONGRESS 1st Session H. R. 5950 IN THE HOUSE OF REPRESENTATIVES November 12, 2021 Ms. Dean (for herself, Mrs. Spartz , Ms. Scanlon , and Mr. Fitzpatrick ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on the Judiciary , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend the Controlled Substances Act to increase the number of days before which certain controlled substances for maintenance or detoxification treatment must be administered, and for other purposes.

1. Short title This Act may be cited as the Improving Patient Access to Care and Treatment Act . 2. Increase in number of days before which certain controlled substances must be administered Section 309A(a)(5) of the Controlled Substances Act ( 21 U.S.C. 829a(a)(5) ) is amended by striking 14 days and inserting 60 days .